Celldex Therapeutics, Inc. — Director's Dealing 2008

Mar 18, 2008

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07

Reporting Person: Elston George (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$8.16	2018-03-07	Common Stock (17879)		Direct

Footnotes

F1: As of March 7, 2008 (the "Effective Date"), George Elston beneficially owns options to purchase 17,879 shares of common stock, par value $0.001 per share (the "Shares"), of AVANT Immunotherapeutics, Inc. Options to purchase 11,368 Shares are exercisable as of the Effective Date. Options to purchase 6,511 Shares will be exercisable on the six-month anniversary of the Effective Date.